With a vote expected shortly, the FDA panel reviewing Human Genome Sciences' (HGSI) lupus drug...

|By:, SA News Editor

With a vote expected shortly, the FDA panel reviewing Human Genome Sciences' (HGSI) lupus drug Benlysta (co-developed by GlaxoSmithKline (GSK)) turns somewhat negative as panel members question whether clinical trials showed real benefits for African Americans - a group more severely affected by the disease. HGSI did not trade today. Update: FDA Panel backs effectiveness of lupus drug. GSK +3.3% AH.